Summary
- Guardant Health derives most of its revenue from FDA-approved liquid-biopsy services as opposed to CLIA-waived laboratory-developed tests "LDT".
- As the FDA prepares to extend its regulatory arm over LDT, it might be a good idea to shift your investment exposure to companies with a favorable regulatory position.
- Beyond regulatory disruptions, GH's market position is influenced by competing dynamics manifested in commercialization challenges weighed against new product introduction tailwinds.
For further details see:
Guardant: Saving Lives One Blood Test At A Time